Quarterly Results
KMTS Earnings Forecast
Looking ahead, KMTS remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Upward by 3.35%, while EPS estimates have been Revise Upward by 4.91%. For the upcoming Q3 2026, revenue estimates have been adjusted Revise Upward by 3.57% . These revisions correlate with a -1.29% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in KMTS long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0

No data
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how KMTS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KMTS sees a +3.14% change in stock price 10 days leading up to the earnings, and a +11.03% change 10 days following the report. On the earnings day itself, the stock moves by +1.62%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in OCT/2025, the stock changed 5.06% on the day following the earnings release and then changed by 8.91% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of KMTS's latest earnings report for ?
KMTS reported its earnings on 2025-12-11, showcasing a revenue of 22.57M against an estimate of 21.22M, resulting in a 6.35% surprise. The EPS was -0.64, surpassing the expected -0.56 by -14.29% . The stock experienced a 5.06% price change on the earnings day and a 7.67% change over the next five days, reflecting market reactions to the results.
How did KMTS's stock price react after the earnings release?
Following KMTS's earnings announcement on 2025-12-11, the stock price moved by 5.06% on the day of the release. Over the subsequent five days, it saw a 7.67% change. Historically, KMTS's stock price tends to shift by an average of +3.14% in the 10 days leading up to earnings and +11.03% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for KMTS for undefined?
For , analysts estimate KMTS’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.35% and EPS estimates Revise Upward by 3.57% over the past three months, indicating analyst expectation in the company’s performance.
How does KMTS's stock price correlate with earnings forecast revisions?
The correlation between KMTS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 3.35%, while EPS estimates moved Revise Upward by 3.57% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from KMTS's next earnings report?
Based on historical trends, KMTS's stock price typically moves by +3.14% in the 10 days before its earnings and +11.03% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .
What is the sentiment in Kestra Medical Technologies Ltd (KMTS) Q2 2026 Earnings Call Summary?
The earnings call reveals strong revenue growth, market expansion, and a strategic focus on innovation. Despite increased losses, cash reserves are robust. The Q&A highlights sustainable growth strategies and positive market reaction to clinical data. The company's guidance and strategic plans suggest a positive outlook, with expected gross margin expansion and increased prescription volumes. While there are uncertainties regarding guideline changes, the overall sentiment is positive, driven by strong financial metrics and optimistic guidance, likely leading to a stock price increase in the short term.

